DMAC Profile
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical firm, is focused on developing innovative treatments for neurological and renal diseases. The company’s flagship drug candidate, DM199, is a recombinant human tissue kallikrein-1 protein currently undergoing clinical evaluation. DM199 is being tested in the Phase 2 REDUX trial for its potential to treat moderate to severe chronic kidney disease associated with Type I or Type II diabetes. Additionally, DM199 is in Phase 2/3 REMEDY2 trials for the treatment of acute ischemic stroke.
Beyond DM199, DiaMedica is advancing DM300, a pre-clinical candidate aimed at addressing inflammatory diseases. This investigational therapy represents the company's broader strategy to target unmet medical needs across various disease states. The pre-clinical development of DM300 reflects DiaMedica's commitment to expanding its pipeline and exploring new therapeutic areas.
DiaMedica Therapeutics Inc., previously known as DiaMedica Inc., rebranded to its current name in December 2016 to better reflect its focus on therapeutic innovations. The company was originally incorporated in 2000 and is headquartered in Minneapolis, Minnesota. Since its founding, DiaMedica has concentrated on advancing its proprietary technologies through clinical trials to bring new treatment options to patients.
With a focus on high-impact medical solutions, DiaMedica Therapeutics is positioned at the forefront of biopharmaceutical research. Its development programs are designed to address significant health challenges, leveraging cutting-edge science to potentially transform the treatment landscape for chronic kidney disease, ischemic stroke, and inflammatory disorders.
|
